Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

At Day 21, low-dose ketamine KET01 shows no statistical edge over placebo

By Brian Buntz | August 14, 2023

KetabonKetabon GmbH revealed positive top-line results from its phase 2 KET01-02 study investigating KET01, an oral slow-release formulation of oral ketamine, for treatment-resistant depression (TRD). Results were promising initially. Investigators noted improvements in depression severity as early as day 4, but data were not statistically significant over placebo at day 21.

A look at Ketabon GmbH’s KET01-02 study in treatment-resistant depression

The trial studied KET01 doses of 120 mg and 240 mg per day. It involved 122 individuals who were outpatients with current major depressive episodes not responding to at least two standard antidepressants. Participants received KET01 once daily in addition to a traditional antidepressant treatment over the three-week period. In particular, the 240 mg/day dose showed clinically relevant improvements with statistical significance versus placebo on days 4 and 7. The drug, however, did not maintain significance at day 21.

Ketabon GmbH touted the data from the phase 2 study, expressing confidence that KET01’s low occurrence of dissociative effects could support the case for at-home use. Ketabon GmbH believes that dissociation has limited ketamine’s adoption.

The trial was conducted at 29 sites across Europe. A partnership between HMNC Brain Health and Develco Pharma, Ketabon GmbH noted that KET-1 was associated with minimal dissociative or cardiovascular side effects.

The trajectory of ketamine in the fight against depression

In a similar vein, Perception Neuroscience, an Atai Life Sciences subsidiary, presented analyses from a double-blind, randomized, placebo-controlled study of the R-isomer of ketamine (arketamine, PCN-101) in TRD at the American Society of Clinical Psychopharmacology (ASCP) 2023 annual meeting on May 31. Although the 60 mg dose showed consistent improvement on the MADRS across all timepoints, the study did not reach its primary efficacy endpoint — improvement in TRD symptoms was non-significant.

The trial enrolled 102 patients with TRD, with 31 subjects in each arm of the study, including placebo, PCN-101 30 mg, and PCN-101 60 mg.

Perception noted that dissociation and sedation were similar to placebo.

More recently, Perception Neuroscience shared data from a phase 1 intravenous-to-subcutaneous (IV-to-SQ) bridging study of PCN-101 (R-ketamine). Focusing on the  safety, tolerability and pharmacokinetics of PCN-101, the study found that the subcutaneous administration was well-tolerated and compared favorably to Spravato (esketamine) in terms of sedation and dissociation rates.

While the off-label use of ketamine to treat depression has exploded in recent years, the dissociative anesthetic has faced challenges. Although Janssen’s esketamine (Spravato) won FDA approval for treatment-resistant depression in 2019, its use has been constrained by the FDA’s Risk Evaluation and Mitigation Strategy (REMS) program, which requires clinician supervision post-administration. Esketamine sales, however, are on the upward trend, hitting $131 million in the first quarter of 2023 — an 87% year-over-year surge.

A number of companies are also working to gain FDA approval for classic psychedelics. The growing traction of alternative mental health treatments, such as ketamine-associated therapy, is fueling research interest in psychedelic therapy.  Decriminalization efforts, efforts, are outpacing clinical development.


Filed Under: Psychiatric/psychotropic drugs
Tagged With: clinical trials, dissociative effects, ketamine, mental health, pharmaceutical industry, phase 2 study, treatment-resistant depression
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Why Cybin’s CEO sees RFK Jr. and J&J’s ketamine clinics as keys to clinical psilocybin’s mainstream moment
Muse Clinic: Innovating with Psychedelics and Neurotechnology
Can LSD break the 20-year drought in anxiety treatment?
MAPS
FDA rejection of MDMA and journal retractions jolt psychedelic therapy research
MDMA
Experts endorse MDMA-assisted therapy for PTSD amid FDA adcomm setback
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE